MOTS-C Dosage: How It's Used

The question “what’s the MOTS-C dosage?” sounds like it should have an answer the way “what’s the dose of ibuprofen?” does. It doesn’t — and the reason is specific to MOTS-C, not a generic disclaimer. This page explains how a dose would actually be decided, why the protocols circulating online are not what they appear to be, and why copying one onto a gray-market vial is a genuinely risky move rather than a shortcut.

Note: This is educational. It is deliberately not a protocol. You will not find a per-injection number, a frequency, or a titration ladder here, because for MOTS-C there is no validated human one to give — and printing a fake-precise one beside an unregulated injectable is the exact harm to avoid.

The thing that makes MOTS-C dosing different

Most “dosage” questions assume a known target. MOTS-C breaks that assumption twice over, and in a way that’s unusual even among research peptides.

First, MOTS-C is not a foreign drug you introduce from scratch. It is a signal your own body already makes. It’s a mitochondrial-derived peptide that circulates naturally, rises when you exercise, and declines as you age (the science of that is covered in what is MOTS-C). That sounds like it should help define a dose — surely you just “top up” what’s falling with age? It does the opposite. A naturally fluctuating internal signal has no single correct blood level to aim for, and “lower with age” is not a deficiency state with a number attached. You cannot reverse-engineer an injection dose from a physiological level the way you’d dose, say, a hormone that has an established replacement target and a lab value to confirm it.

Second — and this is the part most sites quietly skip — there is no completed human efficacy trial of MOTS-C itself. Not an unfinished one. Not a small one. None. The exciting, peer-reviewed biology that makes MOTS-C interesting is overwhelmingly cell-culture and mouse work. There is no human study that took the molecule sold online and established a dose that does anything measurable in people.

Put those together and you get the core point: there is no anchor to dose toward. Every “MOTS-C protocol” you’ve seen is a number invented to fill that vacuum.

Where the internet numbers actually come from

If no human dose exists, where did the confident protocols come from? Two sources, both misrepresented.

Mouse studies. The animal literature is real and reasonably large — researchers have given mice MOTS-C across a range of milligram-per-kilogram doses, from low single digits up into the mid-teens, over weeks. Those studies show genuine metabolic effects in mice. But a milligram-per-kilogram mouse dose is not a human protocol; you cannot scale it across species by simple arithmetic, mice were dosed by intraperitoneal injection in a lab rather than under the skin at home, and a result in a metabolically standardized rodent doesn’t transfer to a person. When a vendor’s “dosing chart” lands suspiciously close to a published mouse figure, that’s not validation — it’s the tell that the number was lifted from an animal paper.

A different molecule that was discontinued. The closest thing to human data is a drug called CB4211, a synthetic analog of MOTS-C — a related but not identical molecule — developed by a company called CohBar. It ran a small early-phase trial in around twenty obese participants with fatty liver, given as a once-daily subcutaneous injection over roughly four weeks. The headline was that it was safe and well tolerated in that short window; it was not a demonstration that it works, the program was paused at one point over injection-site reactions, and CohBar ultimately did not advance it. So the single most-cited “human MOTS-C dosing” reference is: a different molecule, a safety-only study, no efficacy payoff, now shelved. Borrowing its dosing shape to dose MOTS-C is borrowing credibility that the data never earned.

This matters because it explains why the protocols feel authoritative. They cite real papers. They just cite them for something the papers don’t support.

How a dose would actually be decided

When dosing is done properly for any peptide, the number is the last and least interesting part. It is an output of a clinical process, not an input you choose. For MOTS-C specifically, a careful provider would:

• Individualize it. The relevant inputs are the person — their goal, age, sex, metabolic labs, body composition, and how they respond — not a one-size figure. There’s even a wrinkle here: the limited research hints MOTS-C may behave differently in men and women, partly through estrogen interactions, so a single universal number is doubly suspect.
• Set and adjust it over time. A legitimate dose isn’t fixed on day one; it’s chosen conservatively, then revisited based on monitoring and tolerability. That’s a relationship, not a recipe.
• Anchor it to monitoring, not to feelings. MOTS-C is an internal metabolic peptide with no outward signature — no weight drop you can watch like a GLP-1, no color change like a tanning peptide. Whatever it’s doing happens at the level of metabolic markers, which means the honest readout is lab work over weeks to months, tracked with a provider, not a sensation you chase by adding more (the timing of all this is covered in the results timeline).
• Be honest about the evidence. A provider worth seeing will tell you, at the dosing conversation, that the human data is thin and the benefits are not established. If they instead hand you a printed schedule and a vial with total confidence, that confidence is the red flag.

The general principles of how peptide dosing decisions get made are covered in the peptide dosage guide; the MOTS-C-specific lesson is just sharper because there’s so little to anchor to.

Why a fixed internet protocol is unsafe — concretely

This isn’t a generic caution. The specific failure mode for MOTS-C is worth spelling out:

You take a number that was never validated in humans, apply it to a gray-market vial whose actual contents you cannot verify, and inject it on a schedule no clinician set or monitors. Each of those layers compounds the next. The “right” dose of an unverified product is still wrong, because you don’t know how much active peptide is actually in the vial, whether it’s the correct sequence, or what else is in there. Research-use-only and gray-market vials are not held to clinical manufacturing standards, so two vials labeled identically can contain meaningfully different amounts — which makes a precise-looking microgram figure an illusion of control.

And because MOTS-C produces nothing you can feel, you have no feedback loop to catch a problem. With a tanning peptide you’d at least notice an effect; with MOTS-C, a too-high dose, a contaminated batch, or an inert one all feel like nothing. “Inject this schedule and wait” gives you no signal either way.

There are also real safety reasons not to freelance the dose. The research carries a genuinely conflicting cancer signal — some studies explore MOTS-C as a possible cancer therapy while others raise concern about prostate and breast cancer pathways — which is precisely the kind of unresolved question that argues for medical oversight rather than a self-set protocol. And MOTS-C has been prohibited by the World Anti-Doping Agency since 2024, so for any tested athlete the dosing question is moot regardless of the number.

The one warning sign that matters most: a dose offered without an evaluation. A clinic or vendor that gives you a fixed MOTS-C schedule before knowing anything about you — no history, no labs, no follow-up plan — is selling a product, not providing care. The presence of a “protocol” next to a “buy” button is the warning, not the reassurance.

What about “loading phases” and cycling charts?

A lot of MOTS-C protocols come dressed up in pharmacology language — a “loading phase,” a “maintenance dose,” an “on/off cycle.” It’s worth knowing that this vocabulary is borrowed. There is no published human pharmacokinetic study of injected MOTS-C to justify a loading-versus-maintenance structure, and the cycling logic is imported wholesale from how people use growth-hormone secretagogues and other compounds. Dressing a guess in clinical terms doesn’t make it clinical. Treat the elaborate schedule as a sign of confident marketing, not of evidence.

The cleanest “dose” the data actually supports

Here’s the genuinely useful irony. The most robust human-relevant finding about MOTS-C is that your own MOTS-C rises when you exercise — it’s been described as an exercise-induced regulator of metabolic capacity. So the one intervention with real human evidence for raising MOTS-C is physical activity, which is free, safe, has no concentration to verify, and happens to drive every metabolic outcome people hope an injection will deliver.

That’s not a throwaway line. It’s also why injection “results” are so hard to trust: MOTS-C users skew toward people already training, fasting, and optimizing, and exercise itself raises the very peptide they’re injecting — so the lifestyle is tangled with the molecule at the source. If you’re chasing the metabolic benefits MOTS-C is marketed for, the activity that raises your endogenous level is the part of the protocol with actual evidence behind it.

Where MOTS-C stands legally in 2026 (so you know what’s even possible)

The dosing conversation only happens through a legitimate route, and right now that route is unsettled. As of this writing, the correct picture is in motion, not finalized:

• MOTS-C was removed from FDA Category 2 in April 2026 — but removal from Category 2 is not reclassification to Category 1 and not authorization to compound.
• It is on the Pharmacy Compounding Advisory Committee (PCAC) docket for July 23-24, 2026, where it’s being evaluated for obesity and osteoporosis uses among others.
• A PCAC vote is advisory, and formal rulemaking is still pending. Until that finishes, there is no clean, authorized 503A compounding channel for MOTS-C, and anyone telling you it “became legal again” is ahead of the facts.

So the practical answer to “what dose should I take?” in mid-2026 is upstream of dosing entirely: there isn’t yet a fully legitimate supervised channel through which a validated dose would be set, monitored, and refilled. The honest move is to track the regulatory process rather than the protocols. The chronology is laid out in the 2026 FDA reclassification explainer, and the broader picture of what’s legal and what isn’t is in are peptides legal in the US. If you want to understand the actual access routes — telehealth, clinic, prescription — those are covered in how to get MOTS-C, and the side-effect profile that any dosing decision has to weigh is in MOTS-C side effects.

The bottom line

MOTS-C dosing is not a number you copy. It’s a medical decision an individual prescriber makes for an individual patient — and for MOTS-C specifically, it’s a decision made with unusually little to stand on, because no completed human efficacy trial of the molecule has ever set a dose. The figures online are mouse data and a discontinued analog’s safety study wearing a human-protocol disguise. Applied to an unverified vial with no monitoring, the most precise-looking schedule in the world is still a guess injected into the dark. If the metabolic benefits are what you’re after, the exercise that raises your own MOTS-C is the only part of any “protocol” with real human evidence behind it.